Intertumoral heterogeneity has been at the heart of treatment modalities of breast cancer with the success in breast cancer management arising largely from the use of targeted therapy like Tamoxifen in ER+ and Herceptin for the Her2 subtypes. The gene discussed is ERBB2; the disease is breast cancer.